Plasma RANKL levels are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.

Conclusions: These findings suggest that circulating RANKL levels are not associated with breast cancer among BRCA mutation carriers. Pending validation in a larger sample, these findings suggest that RANKL is likely not a biomarker of breast cancer risk among BRCA mutation carriers. PMID: 31069010 [PubMed]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research